Axsome Therapeutics (AXSM) Return on Assets (2016 - 2026)
Axsome Therapeutics (AXSM) reported Return on Assets of 0.0% for Q1 2026, little changed on a YoY basis from 0.0% in Q1 2025, and little changed sequentially from 0.0% in Q4 2025.
Axsome Therapeutics (AXSM) Return on Assets (2016 - 2026) Analysis & Trends
Axsome Therapeutics (AXSM) has 11 years of Return on Assets data on file, last reported at 0.0% in Q1 2026.
- For the quarter ending Q1 2026, Return on Assets changed 0.0% year-over-year to 0.0%; the trailing twelve-month figure through Mar 2026 stood at 0.0% (changed 0.0% YoY), and the FY2025 full-year result was 0.0%, changed 0.0% from the prior year.
- Return on Assets was little changed at 0.0% in Q1 2026, from 0.0% in the prior quarter.
- In the past five years, Return on Assets ranged from a high of 0.0% in Q1 2026 to a low of 0.06% in Q1 2022.
- A 5-year average of 0.01% and a median of 0.0% in 2025 frame the typical range for Return on Assets.
- Across the five-year window, Return on Assets slipped 3 bps in 2022 and gained 5 bps in 2023, its largest moves.
- Tracing AXSM's Return on Assets over 5 years: stood at 0.01% in 2022, then rose by 28 bps to 0.0% in 2023, then dropped by 26 bps to 0.01% in 2024, then soared by 47 bps to 0.0% in 2025, then advanced by 0 bps to 0.0% in 2026.
- Business Quant data shows AXSM's Return on Assets at 0.0% in Q1 2026, 0.0% in Q4 2025, and 0.0% in Q3 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | ROA (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 66,140.12 Bn | 66,139.83 Bn | - | -0.69% |
| 2 | Nanobiotix | 1,908.00 Bn | 1,907.94 Bn | - | - |
| 3 | Akari Therapeutics | 959.56 Bn | 959.56 Bn | - | -0.01% |
| 4 | BeOne Medicines | 471.41 Bn | 466.62 Bn | 1.35 Bn | 0.00% |
| 5 | Vertex Pharmaceuticals | 122.15 Bn | 114.90 Bn | 2.59 Bn | 0.00% |
| 6 | Regeneron Pharmaceuticals | 69.94 Bn | 61.18 Bn | 3.31 Bn | 0.00% |
| 7 | Belite Bio | 62.43 Bn | 62.43 Bn | - | -0.80% |
| 8 | Argenx Se | 55.85 Bn | 50.67 Bn | 1.41 Bn | - |
| 9 | Alnylam Pharmaceuticals | 37.48 Bn | 34.47 Bn | 959.66 Mn | 0.00% |
| 10 | Axsome Therapeutics | 12.25 Bn | 11.94 Bn | 176.48 Mn | 0.00% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 0.00% |
| Dec 31, 2025 | 0.00% |
| Sep 30, 2025 | 0.00% |
| Jun 30, 2025 | 0.00% |
| Mar 31, 2025 | 0.00% |
| Dec 31, 2024 | -0.01% |
| Sep 30, 2024 | -0.01% |
| Jun 30, 2024 | -0.01% |
| Mar 31, 2024 | -0.01% |
| Dec 31, 2023 | 0.00% |
| Sep 30, 2023 | 0.00% |
| Jun 30, 2023 | 0.00% |
| Mar 31, 2023 | 0.00% |
| Dec 31, 2022 | -0.01% |
| Sep 30, 2022 | -0.01% |
| Jun 30, 2022 | -0.02% |
| Mar 31, 2022 | -0.06% |
| Dec 31, 2021 | -0.05% |
| Sep 30, 2021 | -0.04% |
| Jun 30, 2021 | -0.03% |